Cancer

Mouse studies suggest inhibiting BMI1 could help treat castration-resistant prostate cancer (CRPC). In a mouse model of CRPC, a tool compound BMI1 inhibitor decreased tumor growth compared with vehicle. Also in the model, the BMI1 inhibitor plus Xtandi enzalutamide increased progression-free survival (PFS) compared with either agent alone. In an Xtandi-resistant mouse model of CRPC, the combination therapy decreased tumor growth compared with Xtandi alone. Next steps include identifying and testing additional inhibitors of BMI1.

Pfizer Inc. markets Xtandi to treat CRPC...